HIGH confidence: 100% data completeness across all factors and the composite score (25) is in decisive short territory. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Low explanatory power (R² 0.07) — the factor model explains little of this stock's return variation, so these exposures are noisy. Interpret with caution.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-12.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1M— | $583K-56.4% | $0-100.0% | $0n/m | $0n/m |
| EPS (dil.) | $-0.71— | $-0.34n/m | $-0.78n/m | $-0.25n/m | $-1.44n/m |
| Free Cash Flow | -$54M— | -$34Mn/m | -$61Mn/m | -$114Mn/m | -$240Mn/m |
| Gross Margin | 100.0% | 100.0%0.0pp | — | — | — |
| Operating Margin | -4764.3% | -10225.4%-5461.1pp | — | — | — |
| Net Margin | -4897.8% | -11174.8%-6276.9pp | — | — | — |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net insider $103.6M over 180 days (6 open-market buys, 0 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Fewer than 3 analysts refreshed a price target in the last month, so no revision can be computed. Prior quarter: $27 avg across 6 analysts.
Buy-rated share 59% → 65% over ~3 months (+6pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | $-0.27 | $-0.28 | -2.0% |
| Apr 2026 | $-0.33 | $-0.24 | +27.3% |
| Feb 2026 | $-0.10 | $-0.29 | -182.5% |
| Oct 2025 | $-0.18 | $-0.31 | -76.4% |
| Aug 2025 | $-0.09 | $-0.76 | -736.9% |
| May 2025 | $-0.09 | $-0.09 | +3.2% |
| Feb 2025 | $-0.08 | $-0.08 | +0.0% |
| Oct 2024 | $-0.07 | $-0.08 | -14.3% |
The QScore of 25 indicates a relatively weak outlook for Summit Therapeutics, driven down by low scores in Value, Growth, and Profitability, which reflect the company's negative earnings and revenue growth, as well as its high price-to-book ratio of 19.8. Momentum scores slightly higher at 41, due to a recent 3-month return of 22.8%, but this is not enough to offset the overall negative trends. The long-term and short-term scores are relatively close, with only a 6-point difference, suggesting a consistent negative outlook.